Thursday, February 08, 2024
Pacira BioSciences, Inc. (Nasdaq: PCRX), known for its focus on non-opioid pain management and regenerative health solutions, has secured a national group purchasing agreement for Brand Pharmaceuticals with Premier, Inc. This agreement, effective from January 1, 2024, enables Premier members to access special pricing and terms for EXPAREL® (bupivacaine liposome injectable suspension).
The partnership aims to enhance patient care and drive cost efficiencies for healthcare organizations, allowing Premier members to utilize EXPAREL. This innovative single-dose local and regional analgesic offers extended postsurgical pain relief while reducing reliance on opioids.
Pacira BioSciences, expressed enthusiasm about the collaboration, stating, “Premier boasts an extensive network of U.S. hospitals and health systems, presenting Pacira with an exceptional avenue to broaden its reach while elevating patient safety and care. We take pride in partnering with organizations like Premier as we strive to expand access to non-opioid pain management solutions for patients nationwide.”
Aligned in their mission to drive innovation, enhance patient outcomes, and deliver value in healthcare, Pacira and Premier anticipate significant contributions through this collaboration. By uniting approximately 4,350 U.S. hospitals and 300,000 providers, Premier, a leading healthcare improvement company, leverages integrated data, analytics, and various services to facilitate better care and outcomes at reduced costs.